Aerovate Therapeutics Quarterly Balance Sheets Chart
Quarterly
|
Annual
Aerovate Therapeutics Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | |||||||||||||||||
| current assets: | |||||||||||||||||
| cash and cash equivalents | 220,942,000 | 44,220,000 | 33,751,000 | 31,115,000 | 31,069,000 | 9,122,000 | 23,491,000 | 32,180,000 | 60,901,000 | 26,571,000 | 22,397,000 | 22,419,000 | 27,457,000 | 28,137,000 | 54,197,000 | 180,878,000 | 59,150,000 |
| prepaid expenses and other current assets | 2,042,000 | 1,163,000 | 1,494,000 | 1,875,000 | 6,558,000 | 3,905,000 | 1,793,000 | 2,404,000 | 2,374,000 | 1,640,000 | 2,276,000 | 2,578,000 | 1,461,000 | 4,813,000 | 6,958,000 | 2,224,000 | 159,000 |
| total current assets | 222,984,000 | 77,373,000 | 80,117,000 | 90,605,000 | 110,760,000 | 103,239,000 | 124,232,000 | 137,603,000 | 152,470,000 | 120,569,000 | 131,496,000 | 145,156,000 | 153,449,000 | 165,885,000 | 174,333,000 | 183,102,000 | 59,309,000 |
| property and equipment | 147,000 | 2,000 | 6,000 | 14,000 | 232,000 | 260,000 | 288,000 | 316,000 | 245,000 | 267,000 | 242,000 | 330,000 | 316,000 | 288,000 | 186,000 | 162,000 | 35,000 |
| operating lease right-of-use asset | 777,000 | 1,188,000 | 499,000 | 542,000 | |||||||||||||
| other assets | 60,000 | ||||||||||||||||
| total assets | 223,968,000 | 77,533,000 | 80,332,000 | 90,959,000 | 111,694,000 | 106,821,000 | 127,418,000 | 140,876,000 | 155,755,000 | 124,393,000 | 135,301,000 | 147,656,000 | 155,684,000 | 166,999,000 | 175,363,000 | 184,125,000 | 62,434,000 |
| liabilities, convertible preferred stock and stockholders' equity | |||||||||||||||||
| current liabilities: | |||||||||||||||||
| accounts payable | 7,586,000 | 69,000 | 224,000 | 908,000 | 4,179,000 | 3,313,000 | 2,396,000 | 3,504,000 | 5,529,000 | 4,726,000 | 2,575,000 | 4,541,000 | 2,068,000 | 2,863,000 | 1,208,000 | 2,555,000 | 3,042,000 |
| accrued expenses and other current liabilities | 8,091,000 | ||||||||||||||||
| related party accrued expenses and other current liabilities | 2,380,000 | ||||||||||||||||
| warrant liability, related party | 3,563,000 | ||||||||||||||||
| total current liabilities | 21,620,000 | 2,417,000 | 3,828,000 | 10,315,000 | 17,020,000 | 15,518,000 | 17,637,000 | 14,725,000 | 13,284,000 | 10,637,000 | 7,782,000 | 7,705,000 | 3,756,000 | 4,703,000 | 2,550,000 | 3,825,000 | 4,193,000 |
| long-term liabilities: | |||||||||||||||||
| convertible notes payable | |||||||||||||||||
| long-term lease liability | 792,000 | ||||||||||||||||
| total liabilities | 22,412,000 | 2,487,000 | 3,898,000 | 10,466,000 | 17,296,000 | 15,917,000 | 17,962,000 | 15,153,000 | 13,829,000 | 11,298,000 | 8,558,000 | 8,518,000 | 4,631,000 | 5,052,000 | 2,945,000 | 4,277,000 | |
| commitments and contingencies | |||||||||||||||||
| series seed convertible preferred stock, 0.0001 par value; no shares and 20,000,000 shares authorized as of june 30, 2025 and december 31, 2024, respectively; no shares and 20,000,000 issued and outstanding as of june 30, 2025 and december 31, 2024, respectively; liquidation preference of 2 as of december 31, 2024 and none as of june 30, 2025, respectively | |||||||||||||||||
| stockholders’ equity | |||||||||||||||||
| series a non-voting convertible preferred stock, 0.0001 par value; 12,622 and no shares authorized as of june 30, 2025 and december 31, 2024, respectively; 12,622 shares and no shares issued and outstanding as of june 30, 2025 and december 31, 2024, respectively | 2,000 | ||||||||||||||||
| common stock | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | |
| additional paid-in capital | 318,857,000 | 310,563,000 | 309,378,000 | 307,888,000 | 305,863,000 | 277,544,000 | 272,640,000 | 268,926,000 | 265,594,000 | 217,717,000 | 215,110,000 | 212,788,000 | 211,129,000 | 209,891,000 | 208,867,000 | 208,015,000 | 407,000 |
| accumulated other comprehensive loss | -24,000 | -195,000 | -223,000 | -201,000 | -466,000 | -771,000 | -785,000 | -644,000 | -59,000 | ||||||||
| accumulated deficit | -117,282,000 | -235,570,000 | -233,052,000 | -227,622,000 | -211,385,000 | -186,610,000 | -163,424,000 | -143,011,000 | -123,448,000 | -104,423,000 | -87,903,000 | -72,881,000 | -59,293,000 | -47,302,000 | -36,392,000 | -28,169,000 | -21,985,000 |
| total stockholders’ equity | 201,556,000 | 75,046,000 | 76,434,000 | 80,493,000 | 94,398,000 | 90,904,000 | 109,456,000 | 125,723,000 | 141,926,000 | 113,095,000 | 126,743,000 | 139,138,000 | 151,053,000 | 161,947,000 | 172,418,000 | 179,848,000 | |
| total liabilities, series seed convertible preferred stock and stockholders' equity | 223,968,000 | ||||||||||||||||
| short-term investments | 31,990,000 | 44,872,000 | 57,615,000 | 73,133,000 | 90,212,000 | 98,948,000 | 103,019,000 | 89,195,000 | 92,358,000 | 106,823,000 | 120,159,000 | 124,531,000 | 132,935,000 | 113,178,000 | |||
| operating lease right-of-use assets | 158,000 | 209,000 | 259,000 | 621,000 | 725,000 | 614,000 | 713,000 | 811,000 | 908,000 | 1,003,000 | 1,094,000 | 583,000 | |||||
| | |||||||||||||||||
| liabilities and stockholders’ equity | |||||||||||||||||
| accrued and other current liabilities | 2,036,000 | 3,187,000 | 8,948,000 | 12,366,000 | 11,760,000 | 14,821,000 | 10,770,000 | 7,376,000 | 5,538,000 | 4,822,000 | 2,785,000 | 1,341,000 | 1,647,000 | 1,150,000 | 1,123,000 | 1,151,000 | |
| operating lease liabilities | 312,000 | 417,000 | 459,000 | 475,000 | 445,000 | 420,000 | 451,000 | 379,000 | 373,000 | 385,000 | 379,000 | 147,000 | |||||
| other liabilities | 70,000 | 70,000 | 70,000 | 70,000 | 70,000 | 70,000 | 70,000 | 69,000 | 70,000 | 71,000 | 13,000 | 13,000 | 14,000 | 13,000 | |||
| stockholders’ equity: | |||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized as of march 31, 2025 and december 31, 2024, respectively; no shares issued and outstanding at march 31, 2025 and december 31, 2024, respectively | |||||||||||||||||
| accumulated other comprehensive gain | 50,000 | 105,000 | 224,000 | ||||||||||||||
| total liabilities and stockholders’ equity | 77,533,000 | 80,332,000 | 90,959,000 | 111,694,000 | 106,821,000 | 127,418,000 | 140,876,000 | 155,755,000 | 124,393,000 | 135,301,000 | 147,656,000 | 155,684,000 | 166,999,000 | ||||
| other long-term assets | 81,000 | 81,000 | 2,597,000 | 2,284,000 | 2,244,000 | 2,229,000 | 2,649,000 | 2,560,000 | 1,076,000 | 731,000 | 327,000 | 302,000 | 278,000 | 3,090,000 | |||
| operating lease liabilities, net of current portion | 81,000 | 206,000 | 329,000 | 255,000 | 358,000 | 476,000 | 591,000 | 705,000 | 800,000 | 862,000 | 335,000 | 382,000 | 452,000 | ||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized as of december 31, 2024 and december 31, 2023, respectively; no shares issued and outstanding at december 31, 2024 and december 31, 2023, respectively | |||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized as of september 30, 2024 and december 31, 2023, respectively; no shares issued and outstanding at september 30, 2024 and december 31, 2023, respectively | |||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized as of june 30, 2024 and december 31, 2023, respectively; no shares issued and outstanding at june 30, 2024 and december 31, 2023, respectively | |||||||||||||||||
| accumulated other comprehensive income | -83,000 | -33,000 | 237,000 | ||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized as of march 31, 2024 and december 31, 2023, respectively; no shares issued and outstanding at march 31, 2024 and december 31, 2023, respectively | |||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized as of december 31, 2023 and december 31, 2022, respectively; no shares issued and outstanding at december 31, 2023 and december 31, 2022, respectively | |||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized as of september 30, 2023 and december 31, 2022, respectively; no shares issued and outstanding at september 30, 2023 and december 31, 2022, respectively | |||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized as of june 30, 2023 and december 31, 2022, respectively; no shares issued and outstanding at june 30, 2023 and december 31, 2022, respectively | |||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized as of march 31, 2023 and december 31, 2022, respectively; no shares issued and outstanding at march 31, 2023 and december 31, 2022, respectively | |||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized as of december 31, 2022 and december 31, 2021, respectively; no shares issued and outstanding at december 31, 2022 and december 31, 2021, respectively | |||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized as of september 30, 2022 and december 31, 2021, respectively; no shares issued and outstanding at september 30, 2022 and december 31, 2021, respectively | |||||||||||||||||
| operating lease liability | 347,000 | 193,000 | 192,000 | ||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized as of june 30, 2022 and december 31, 2021, respectively; no shares issued and outstanding at june 30, 2022 and december 31, 2021, respectively | |||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized and no issued or outstanding as of march 31, 2022 and december 31, 2021 | |||||||||||||||||
| liabilities, redeemable convertible preferred stock and stockholders’ equity | |||||||||||||||||
| series a redeemable convertible preferred stock, 0.0001 par value; 0 and 40,052,154 shares authorized at december 31, 2021 and december 31, 2020, respectively; 0 and 6,489,534 shares issued and outstanding at december 31, 2021 and december 31, 2020, respectively | |||||||||||||||||
| series seed redeemable convertible preferred stock, 0.0001 par value; 0 and 4,000,000 shares authorized, issued and outstanding at december 31, 2021 and december 31, 2020, respectively | |||||||||||||||||
| temporary equity value | |||||||||||||||||
| total liabilities, redeemable convertible preferred stock and stockholders’ equity | 175,363,000 | 184,125,000 | |||||||||||||||
| series a redeemable convertible preferred stock, 0.0001 par value; 0 and 40,052,154 shares authorized at september 30, 2021 and december 31, 2020, respectively; 0 and 6,489,534 shares issued and outstanding at september 30, 2021 and december 31, 2020, respectively | |||||||||||||||||
| series seed redeemable convertible preferred stock, 0.0001 par value; 0 and 4,000,000 shares authorized, issued and outstanding at september 30, 2021 and december 31, 2020, respectively | |||||||||||||||||
| redeemable convertible preferred stock | |||||||||||||||||
| liabilities, redeemable convertible preferred stock and stockholders' deficit | |||||||||||||||||
| series a redeemable convertible preferred stock, 0.0001 par value; | |||||||||||||||||
| 40,052,154 shares authorized at june 30, 2021 and december 31, 2020; 40,052,154 and | |||||||||||||||||
| 6,489,534 shares issued and outstanding at june 30, 2021 and december 31, 2020, | |||||||||||||||||
| respectively; aggregate liquidation preference of 75,819 at june 30, 2021 | 75,819,000 | ||||||||||||||||
| series seed redeemable convertible preferred stock, 0.0001 par value; | |||||||||||||||||
| 4,000,000 shares authorized, issued and outstanding at june 30, 2021 and | |||||||||||||||||
| december 31, 2020; aggregate liquidation preference of 4,000 at june 30, 2021 | 4,000,000 | ||||||||||||||||
| stockholders' deficit: | |||||||||||||||||
| december 31, 2020, respectively; 243,076 shares issued and outstanding at | |||||||||||||||||
| june 30, 2021 and december 31, 2020, respectively | |||||||||||||||||
| total stockholders' deficit | -21,578,000 | ||||||||||||||||
| total liabilities, redeemable convertible preferred stock and stockholders’ deficit | 62,434,000 |
We provide you with 20 years of balance sheets for Aerovate Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Aerovate Therapeutics. Explore the full financial landscape of Aerovate Therapeutics stock with our expertly curated balance sheets.
The information provided in this report about Aerovate Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.